Archive | Artificial Intelligence (AI) RSS feed for this section

Automating Cancer Imaging Analysis – Interview with Joe Camaratta, President & CEO of Quantaras

26 Oct

By Erika Wu, Business Development Representative, LSN

Earlier this year, Quantaras (formerly known as Quantitative Radiology Solutions, QRS) received 510(k) clearance from the FDA and is now actively launching their AI-based technology to healthcare providers in the United States. Tune in and learn how Joe Camaratta, President & CEO of Quantaras, and his team are revolutionizing personalized cancer treatment decisions with the automation of medical imaging analysis. Digital RESI November (16-18) returns with dynamic panels, as well as opportunities to pitch to a live panel of investors. Learn more about how you can get involved and tell your story at November’s Innovator’s Pitch Challenge!


AI Diagnostics from Oncology, Cardio, and Beyond – Interview with Jonathan Cohen, JD, Founder & CEO of 20/20 Gene Systems

19 Oct

By Erika Wu, Business Development Representative, LSN

Past RESI AI panelist, Jonathan Cohen returns to give an update on 20/20 Gene Systems, including an expansion from cancer detection to respiratory and cardiovascular diagnostics. Learn how Jonathan and the team are using Artificial Intelligence (AI) to expand their offerings, and how they’re working to create more opportunities for early-stage diagnostic startups. Digital RESI November (16-18th) returns with dynamic panels, as well as opportunities to pitch to a live panel of investors. Learn more about how you can get involved and tell your story at November’s Innovator’s Pitch Challenge!


RESI AI Innovator’s Pitch Challenge Winners

23 Sep

By Rory McCann, Marketing Manager & Conference Producer, LSN

Last week’s digital RESI AI conference connected early-stage AI startups with the investors, service providers, and strategic partners founders are looking for. The conference featured insightful panels, educational workshops, fit-focused partnering, and opportunities for fundraising entrepreneurs to pitch directly to a panel of investors, such as the Innovator’s Pitch Challenge (IPC).

Innovator’s Pitch Challenge winners were selected by attendees for the best pitch. Each company submitted marketing materials and a pitch video to their dedicated webpage, available to view by all attendees and judges. The live session included elevator pitches and time for Q&A with the judges and audience.

Congratulations to our IPC winners! Click the logos to learn more about each company:

Session 1 (Devices and Therapeutics) Winner


NeoPrediX develops decision support tools with maternal, neonatal and perinatal screening platforms to evaluate, optimize and personalize medical strategies in pediatrics. We utilize intelligent algorithms and digital health solutions for neonatal and perinatal care based on deep medical data and science, developed by experienced scientists, pediatricians, and neonatologists.

Session 2 (R&D/Manufacturing Services and Digital Health) Winner


SingularityAI builds an AI-driven medical image and data analytics platform of cloud software and smart devices with data privacy preserving technologies, to make AI-driven insights a broad reality for medical innovation.

Interested in joining the RESI November IPC? Apply today and save on super early bird rates! Applications are accepted on a rolling basis, so get started today!


RESI Partnering Week Final Agenda

9 Sep

By Karen Deyo, Director of Investor Research, Israel BD, LSN

RESI Partnering Week, September 13-17, launches next week and featuring a star-studded lineup of panel discussions, live pitch sessions, educational workshops, fireside chats, and partnering. Check out our lineup of pre-recorded content, as well as the schedule of live events across Digital RESI September, RESI AI, and RESI Longevity.

If you haven’t yet signed up to start booking meetings and connecting with investors who are a fit for your product and stage of development, there is still time. Sign up today!

Digital RESI
(September 13-15)
  Monday (9/13) Tuesday (9/14) Wednesday (9/15)
9:00 EDT   Company Valuation for Fundraising Workshop  
10:00 EDT Medical Devices Panel Asia Cross-Border Panel Corporate VC Panel
11:00 EDT IPC Session 1: Therapeutics Beyond Banking: Finding the Right Financial Partner for You Negotiating Term Sheets Workshop
12:00 EDT Seed Funds Panel Tales from the Road Panel Angels & Family Offices Panel
13:00 EDT IPC Session 2: Diagnostics UCSF Innovation Ventures and Entrepreneurship Program Workshop Financing Scientific Instrumentation as a Startup Company Workshop
IPC Session 5: Oncology
14:00 EDT Big Pharma Panel Mental & Behavioral Health Panel IPC Session 8: R&D / Manufacturing Services
15:00 EDT IPC Session 3: Novel Drug Delivery Fundraising Bootcamp Workshop How to Evaluate Your Banking Partner Workshop
16:00 EDT IPC Session 4: Cardiovascular & Ophthalmic Disorders IPC Session 6: Medical Devices IPC Session 9: Therapeutics
17:00 EDT Why US Biotechs are Coming to Australia… Workshop IPC Session 7: Therapeutics IPC Session 10: Medical Devices & Digital Health
RESI AI & RESI Longevity
(September 16-17)
  Thursday (9/16) Friday (9/17)
10:00 EDT Healthcare Communications Panel Accelerated Pharma Development Panel
Social Isolation & Loneliness Panel Health & Homecare Panel
11:00 EDT   Commercialization of AI Technologies Workshop
Medical Accountability & Adherence Panel
12:00 EDT IPC Session 1: Therapeutics & Devices IPC Session 2: Digital Health and R&D/Manufacturing
Designing Innovation in Assisted Living and Aging in Place
13:00 EDT IPC Session 1: Medical Devices IPC Session 3: Digital Health
14:00 EDT   Diagnostic Wearables Panel
Funding and Strategic Directions with the National Institute on Aging Fireside Chat
15:00 EDT IPC Session 2: Diagnostics & Therapeutics What Angels, Seed, Venture, Corporate and Family Offices Investors Are Looking For Panel
16:00 EDT Healthcare Systems and Infrastructure Panel Precision Medicine Panel
Creating Better Dementia Care and Promoting Brain Health Panel
  Pre-Recorded Sessions
  Fundraising Bootcamp Workshop
  The Future of Wearables and Older Adults 2021
  Portfolio Spotlight with Mary Furlong & Associates (MFA)
  National Institute on Aging Seed Funding Overview and Portfolio Showcase
  Fundraising Bootcamp Workshop

700+ Investors at RESI Partnering Week

9 Sep

By Joey Wong, Investor Research Analyst, LSN

700+ investors representing VC, Corporate VC, Big Pharma, Angels, Family Offices, and more are meeting virtually across RESI Partnering Week, September 13-17. There is still time to sign up and start booking meetings. The RESI partnering platform is enabled to narrow down searches for investors who are a fit for your product, stage of development, and specific needs unique to your company. Check out the firms attending this week and select the conference you’re interested in to see the firms participating.

RPW Sept. 2021 Confirmed Investors
Confirmed RESI Investors Confirmed RESI AI Investors Confirmed RESI Longevity Investors
As of September 8

Meet the Innovator’s Pitch Challenge (IPC) Finalists of RESI Partnering Week

2 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN


Life Science Nation (LSN) is pleased to announce the Innovator’s Pitch Challenge (IPC) finalists who will be presenting at the upcoming RESI Partnering Week, September 13-17. The IPC continues to see a record number of applicants, establishing itself as a differentiated and effective platform to showcase innovative technologies during a virtual conference age.

Each participating company will have a dedicated landing page with their pitch video and supplementary materials and will participate in a live Q&A session with investors and industry experts providing feedback and questions, which will help companies better prepare for future investor meetings, understand investor perspectives, and enhance their visibility and network. Many past participants have credited the IPC to unexpected follow-up meetings and new connections.

RESI Partnering Week attendees do not want to miss out on these engaging sessions! If you are not registered, it is not too late – you can register here. If you are an active investor interested in getting involved with these sessions, please reach out to for more information.

Below are the participating companies – please click on their logos to learn more!


Artificial Intelligence for Quality Management in Radiology

30 Aug

Aviel Blumenfeld

Interview with Aviel Blumenfeld, CEO & Co-Founder of IMedis


By Erika Wu, Business Development Representative, LSN

Aviel Blumenfeld is the CEO & Co-Founder of IMedis, an Israeli-based company that is creating a comprehensive quality management platform for radiology departments using ground-breaking AI technology to improve clinical outcomes, reduce risks of wrong diagnosis, and increase efficiency. IMedis’ solution uses a unique combination of image analysis and text analysis using AI for the detection and surfacing of various failure points throughout the radiology workflow. In addition, IMedis has a strong and cohesive team and is backed by a leading digital health VC. With a growing pipeline of collaborations in pilots, the company is exactly at the deflection point for using digital health for promoting quality-based healthcare. Aviel has worked in the medical devices field for 15 years in various positions including clinical applications specialists, software engineer, algorithm engineer, product manager and VP of R&D. At IMedis, Aviel handles management, strategy, operation, business development and fundraising. 

Erika Wu (EW): IMedis pitched at the Innovator’s Pitch Challenge at RESI AI, January 2021 and Digital RESI, March 2021. What are you currently doing to grow IMedis and where is the company right now?

Aviel Blumenfeld (AB): IMedis is focusing on its go-to-market strategy and has already had several first early adopters in the US and UK starting to use Duali-Q for surfacing actionable missed findings in radiology reports. We expect to receive our first FDA clearance for our clinical offering by early 2022 and to start accelerating our commercial activity and growth of the company. Later this year we are planning to have our Series A-round in order to support the early stage of commercialization of the company, expedite development of new solutions and regulatory approvals.

EW: How would you describe AI?

AB: Professionals’ best assistance.

EW: As many were in your shoes at one point, what are some challenges you’ve learned from? Can you provide any advice, and how has your findings impacted your plan moving forward?

AB: In every conversation, you can learn something new, so keep close relationships with your potential customers, users and partners to better understand their needs and motivation. Early stages of a startup company are very fragile. When the pandemic started we were afraid that we would completely lose the attention of our target customers in the US while they were focused on treating COVID patients and significantly reducing their capacity of radiological examinations. We adopted our go-to-market strategy quickly and approached a new geographical market in the UK as we recognized the NHS which strengthened its digital adoption and openness to new technologies. The benefits of our solution are, first of all, for the patients with improved health outcomes, but also for large health systems by promoting early detection of life-threatening diseases — this is why we see a great potential in the UK as well as with large health systems in the US. We are aiming to keep developing our platform to cover more and more potential failure points and to offer the first in kind comprehensive solution for quality assurance in radiology.

Learn more about IMedis and connect with AI investors at Digital RESI AI (September 16-17)! 

%d bloggers like this: